share_log

Evelo Biosciences | 15-12G: Notice of termination of registration of a class of securities under Section 12(g) (and amendment thereto)

Evelo Biosciences | 15-12G:終止註冊

美股sec公告 ·  01/27 06:36
牛牛AI助理已提取核心訊息
Evelo Biosciences, Inc. has officially filed a Form 15 with the United States Securities and Exchange Commission (SEC) to terminate its registration under Section 12(g) of the Securities Exchange Act of 1934, as well as to suspend its duty to file reports under Sections 13 and 15(d) of the same act. The filing indicates that Evelo Biosciences will no longer be required to file periodic financial reports with the SEC. The decision to deregister was made under Rule 12g-4(a)(1) and Rule 15d-6, as marked on the form. The company reported approximately 36 holders of record as of the notice date. The certification was signed by Craig R. Jalbert, the Chief Executive Officer, President, and Director of Evelo Biosciences, on January 26, 2024.
Evelo Biosciences, Inc. has officially filed a Form 15 with the United States Securities and Exchange Commission (SEC) to terminate its registration under Section 12(g) of the Securities Exchange Act of 1934, as well as to suspend its duty to file reports under Sections 13 and 15(d) of the same act. The filing indicates that Evelo Biosciences will no longer be required to file periodic financial reports with the SEC. The decision to deregister was made under Rule 12g-4(a)(1) and Rule 15d-6, as marked on the form. The company reported approximately 36 holders of record as of the notice date. The certification was signed by Craig R. Jalbert, the Chief Executive Officer, President, and Director of Evelo Biosciences, on January 26, 2024.
Evelo Biosciences, Inc.已正式向美國證券交易委員會(SEC)提交了15號表格,要求終止其根據1934年《證券交易法》第12(g)條的註冊,並暫停其根據該法第13和15(d)條提交報告的義務。該文件表明,Evelo Biosciences將不再需要向美國證券交易委員會提交定期財務報告。取消註冊的決定是根據第12g-4(a)(1)條和第15d-6條做出的,如表格上所示。截至通知之日,該公司報告了約36名登記持有人。該認證由Evelo Biosciences首席執行官、總裁兼董事克雷格·賈爾伯特於2024年1月26日簽署。
Evelo Biosciences, Inc.已正式向美國證券交易委員會(SEC)提交了15號表格,要求終止其根據1934年《證券交易法》第12(g)條的註冊,並暫停其根據該法第13和15(d)條提交報告的義務。該文件表明,Evelo Biosciences將不再需要向美國證券交易委員會提交定期財務報告。取消註冊的決定是根據第12g-4(a)(1)條和第15d-6條做出的,如表格上所示。截至通知之日,該公司報告了約36名登記持有人。該認證由Evelo Biosciences首席執行官、總裁兼董事克雷格·賈爾伯特於2024年1月26日簽署。

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生,只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。